Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-09-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于新型冠状病毒mRNA疫苗获得印度尼西亚紧急使用授权（EUA）的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of an emergency use authorization (EUA) for a new mRNA COVID-19 vaccine in Indonesia. It includes details about the regulatory approval, clinical trials, and strategic partnerships but does not contain financial statements or detailed financial performance data. The document length is 1761 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a regulatory filing in the sense of compliance or certification, nor is it a voting or governance related document. The content focuses on a significant product approval and market expansion update, which fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-09-30 Chinese
关于监事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of the supervisory board (监事会换届选举) of the company 云南沃森生物技术股份有限公司. It details the nomination of a candidate for the supervisory board, the legal basis for the election, and the process for shareholder approval. There is no financial data, no mention of annual or interim reports, no audit information, and no other types of filings such as earnings releases or capital changes. The content is about changes in the company's supervisory board, which falls under management or board information. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or a regulatory filing. Confidence is high due to clear content about board member election.
2022-09-27 Chinese
独立董事提名人声明（赵健梅）
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It details the nominee's qualifications, compliance with relevant laws and regulations, and declarations regarding independence and eligibility. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically about a director nomination. Therefore, the document fits the category of Board/Management Information (MANG). The document length is over 6000 characters, indicating it is a full statement rather than a brief announcement or certification.
2022-09-27 Chinese
独立董事提名人声明（孙钢宏）
Board/Management Information Classification · 100% confidence The document is a formal public statement from the board of directors nominating an individual as an independent director candidate. It includes detailed declarations about the nominee's qualifications, compliance with relevant laws and regulations, and independence criteria. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes, specifically the nomination of a new independent director. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not merely an announcement or certification.
2022-09-27 Chinese
独立董事候选人声明（赵健梅）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, detailing compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and adherence to relevant laws and regulations. There is no financial data, no discussion of company performance, no voting results, no meeting materials, and no mention of report publication. The content is focused on governance and compliance related to board membership. Therefore, this document fits best under Board/Management Information (MANG), as it relates to the announcement and declaration concerning a board member candidate's qualifications and independence.
2022-09-27 Chinese
独立董事关于续聘公司2022年度审计机构的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval for the reappointment of the company's 2022 audit firm. It references regulatory rules and the audit firm qualifications but does not contain any audit report, financial statements, or detailed audit results. The document is short (527 characters) and serves as an opinion or approval related to the audit firm appointment rather than the audit report itself. Therefore, it is not an Audit Report (AR) but rather a regulatory or governance-related filing. Given the nature of the document as an official opinion on audit firm reappointment, it fits best under Regulatory Filings (RNS) as it does not meet the criteria for a full audit report or annual report.
2022-09-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.